Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
XenoGesis
XenoGesis
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Quay Pharma partners with XenoGesis on drug development
The partnership aims to accelerate the drug development process for both companies’ clients
Research & Development
Contract research organisation XenoGesis expands services
Nottingham, UK-based firm adds CYP induction and gene expression assay services to portfolio
Research & Development
XenoGesis aims to expand into US market
Appoints Sabrina Mogle as a business development specialist to spearhead growth in the region
Research & Development
XenoGesis strengthens DMPK team with appointment of Peter White
He specialises in mass spectrometry and bioanalysis
Research & Development
XenoGesis invests in new cutting-edge technology
Will allow the DMPK and bioanalysis specialist to increase capacity and add new capabilities
Research & Development
XenoGesis appoints Director of External Projects
Graham Trevitt joins the Nottingham, UK-based contract research organisation
Research & Development
UK companies Molecular Profiles and XenoGesis forge partnership
Nottingham-based companies will support drug developers during pre-clinical and formulation stages
Subscribe now